Faeth Therapeutics, Inc. FTH
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -26.15%
- 1 year
- -10.45%
5D -1.47 (-14.47%)
- Market cap
- 203.65M
- EPS (ttm)
- -22.50
- Shares out
- 25.84M
- Forward P/E
- -7.88
- YTD return
- -26.15%
- 1-year return
- -10.45%
- 50-day average
- 30.99
- 200-day average
- 22.28
- Enterprise value
- 781.62M
- Volume
- 419.11K
- Avg volume
- 500.48K
- Open
- 8.52
- Previous close
- 8.69
- Day's range
- 7.85 – 9.13
- 52-week range
- 7.45 – 42.14
- Beta
- -0.28
- Analysts
- Strong Buy
- Price target
- 54.64 (+593.4%)
Key statistics
- Price / book
- 5.84
- Free cash flow
- 855.13K
- Total cash
- 186.44M
- Total debt
- 592.00K
- Return on equity
- -195.26%
- Short % of float
- 4.32%
Fundamental scorecard
3 of 25 checks passed on FTH’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2026 | Sep 30, 2026 | -0.66 | — | — | — |
| Aug 4, 2026 | Jun 30, 2026 | -2.64 | -2.84 | -0.20 | -7.58% |
| May 15, 2026 | Mar 31, 2026 | -0.62 | -131.45 | -130.83 | -21,101.61% |
| Mar 30, 2026 | Dec 31, 2025 | -4.81 | -3.74 | +1.07 | +22.25% |
| Nov 14, 2025 | Sep 30, 2025 | -4.11 | -3.62 | +0.49 | +11.92% |
| Aug 5, 2025 | Jun 30, 2025 | -6.20 | -3.91 | +2.29 | +36.94% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 14, 2026 | LUCID CAPITAL MARKETS | init | — | Buy |
| Sep 9, 2026 | TD Cowen | init | — | Buy |
| Aug 21, 2026 | Needham | init | — | Buy |
| Aug 11, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 4, 2026 | Jones Trading | init | — | Buy |
| Jul 31, 2026 | Raymond James | init | — | Outperform |
About Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- faeththerapeutics.com
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
Faeth Therapeutics Enters Into Clinical Trial Collaboration And Supply Agreement With Roche To Evaluate PIKTOR In Combination With Investigational Medicine Giredestrant In Patients With HR+/HER2- Advanced Breast Cancer
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60
Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results
12 Health Care Stocks Moving In Monday's Intraday Session
Dow Jumps Over 600 Points; Constellation Energy Posts Upbeat Earnings Faeth Therapeutics Announces Data From Its Phase 2 Study Of PIKTOR Shows Confirmed Objective Response Rate OF 33%, Disease Control Rate Of 83%
12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on FTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAMBRIAN BIOPHARMA INC | Beneficial Owner of more than 10% of a Class of Security | Sale | May 31, 2026 | 130,142 |
| HAHN STEPHEN M | Director | Conversion of Exercise of derivative security | Jun 14, 2026 | 44,763 |
| MILLENNIUM MANAGEMENT, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 6, 2026 | 0 |
| PARIKH ANAND KIRAN J.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Jun 21, 2026 | 817,699 |
| PEYER JAMES | Beneficial Owner of more than 10% of a Class of Security | Sale | May 31, 2026 | 130,142 |
| STEPHENSON BRIAN C | Chief Financial Officer | Purchase | Jun 30, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 7.82% | 2,020,103 | 78.97M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.59% | 1,444,039 | 56.45M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 4.98% | 1,286,411 | 50.29M | Jun 29, 2026 |
| Balyasny Asset Management LP | 4.03% | 1,042,198 | 40.74M | Jun 29, 2026 |
| Cormorant Asset Management, LP | 3.98% | 1,028,242 | 40.19M | Jun 29, 2026 |
| RA Capital Management, L.P. | 2.79% | 722,020 | 28.22M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.19% | 48,771 | 1.91M | Apr 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 0.06% | 15,907 | 621.80K | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.04% | 10,115 | 395.39K | Jun 29, 2026 |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 0.02% | 4,560 | 178.25K | Jul 30, 2026 |
| Dimensional ETF Trust-Dimensional U.S. Small Cap ETF | 0.01% | 1,360 | 53.16K | Apr 29, 2026 |
| iShares Trust-iShares Micro-Cap ETF | 0.01% | 3,192 | 124.78K | Jun 29, 2026 |
